Κατάλογος Προσωπικού

ΤΡΙΑΝΤΑΦΥΛΛΟΣ ΣΤΥΛΙΑΝΟΠΟΥΛΟΣ

STYLIANOPOULOS TRIANTAFYLLOS
+357 2289 2238
...
ΑΝΑΠΛΗΡΩΤΗΣ/ΡΙΑ ΚΑΘΗΓΗΤΗΣ/ΡΙΑ
Τμήμα Μηχανικών Μηχανολογίας και Κατασκευαστικής
Green Park, 507
Λεωφ. Αγλαντζιας 91
Diploma in Chemical Engineering, 2003
National Technical University of Athens, Greece
 
PhD in Chemical Engineering, 2008
University of Minnesota, USA
 
Postdoctoral training, Department of Radiation Oncology
Massachusetts General Hospital / Harvard Medical School, USA
  
Triantafyllos received a Diploma in Chemical Engineering from National Technical University of Athens, Greece (GPA: 9.34/10) in 2003. The same year he joined the Chemical Engineering graduate program at the University of Minnesota, USA to pursue his doctoral studies. He worked with Professor Victor Barocas on modeling the mechanical response of native and bioartificial tissues. During his doctoral studies, he was elected twice top doctoral student of the department. After the completion of his PhD., in May 2008, Triantafyllos joined Dr. Rakesh Jain's lab in the department of Radiation Oncology at Harvard Medical School and Massachusetts General Hospital, USA for his prostodoctoral training. In Dr. Jain's lab he performed research in a mixture of experimental and computational problems for optimizing the delivery of molecular and nanoscale medicine to solid tumors. In September 2010, he joined the faculty of the Mechanical and Manufacturing Engineering department at the University of Cyprus.
 
Triantafyllos has co-authored over 150 publications in peer-review journals. His publication record includes five articles in Nature journals (Nature Nanotechnology, Nature Medicine, two articles in Nature Communications and two articles in Nature Reviews Clinical Oncology), eleven articles in PNAS, two in Cancer Research as well as articles in Clinical Cancer Research and ACS Nano. h-index:54, > 14,000 citations (Web-of-Science) | h-index:58, > 20,000 citations (GoogleScholar).
 
He has received all 3 highly selective research grants by the European Research Council (ERC Starting Grant ReEngineeringCancer, 2014-2018, 1.44M euros, ERC Consolidator Grant Immuno-Predictor, 2020-2025, 2.0M euros and ERC Advanced Grant MechanoResistance, 2025-2030, 2.5M euros) as well as the prestigious Y. C. Fung Early Carrer award by the American Society of Mechanical Engineers in 2016 (https://www.asme.org/about-asme/participate/honors-awards/achievement-awards/y-c-fung-young-investigator-award) and the UNESCO-Equitorial Guinea Prize for Research in Life Science (2024) (https://www.unesco.org/en/articles/laureates-china-egypt-and-greece-win-unesco-equatorial-guinea-international-prize-research-life).
 
Triantafyllos was also the recipient of the 2014 Most Cited Paper Award and the 2019 Best Student paper Award by the Biomedical Engineering Society (BMES) of the USA. At National level, Triantafyllos is the first researchers in UCY to have received both the New Researcher Award (2014) and the Distinguished Researcher Award (2021) by the Research and Innovation Foundation of Cyprus.   
 
The last years, Triantafyllos has received as a Prinicipal Investigator ~ 10.0 Millions in Research funding, including 10 grants from FP7, Horizon2020, Horizon Europe and 2 grants from Research and Innovation Foundation of Cyprus. 
 
Triantafyllos is a member of the American Society of Mechanical Engineers, the Biomedical Engineering Society of the USA, the American Association of Cancer Research, the European Foundation of Clinical Nanomedicine and the European Society of Biomechanics.

The major focus of my current research is on the biomechanics and drug delivery of solid tumors. I use experimental methods in mice bearing tumors and in vitro tumor models as well as mathematical modelling to study the evolution of mechanical forces in tumors and how these forces correlate with tumors' patho-physiology and delivery of chemotherapy, nanomedicine and immunotherapy. Furthermore, I investigate strategies to optimise tumor blood vessel functionality in order to improve systemic delivery of cancer therapeutics by modifying the mechanical tumor micro-environment.

 FUNDING

Principal Investigator

European Research Council Consolidator Grant (ERC-CoG): Immuno-Predictor: Mechanical Biomarkers for Cancer Immunotherapy Prediction. April 2020 - March 2025 , €2,000,000
 
Horizon 2020 - Marie Skłodowska-Curie Actions Individual Fellowship Global (MSCA-IF-GF-2020-101028945 CancerCOtreat): Optimizing treatment of cancer patients infected with COVID-19 and other preconditions using mathematical modelling. May 2021 – April 2024; €256,236.

 

Horizon Europe, Marie Skłodowska-Curie Individual Fellowship, (MSCA-2021-PF-101065325, DL- ElastoMark), "A deep learning-derived, shear wave elastography biomarker for cancer therapy prediction". September 2022 - August 2024. €148,488.

European Research Council, Proof of Concept grant (ERC-2022-PoC1-101069207, DL-MechanoPredictor), “Deep learning derived mechanical biomarkers for cancer therapy prediction”, September 2022 - March 2024. €150,000.

European Research Council, Proof of Concept grant (ERC-2022-PoC2), LiveBioThx), “Live biotherapeutics to potentiate cancer immunotherapy”, March 2023 – August 2024. €150,000.
 
Partner 

National Institutes of Health (1 R01 EB032655-01A1): "A novel paradigm of sensitization of the tumor microenvironment with image-guided ultrasound cavitation and mechanotherapeutics for targeted HCC treatment", University of Cyprus budget: $121,000. PI: Professor Mike Averkiou, Department of Bioengineering, University of Washington in Seattle. September 2022-August 2026.

Horizon 2020, European High-Performance Computing Joint Undertaking (H2020-JTI-EuroHPC-2019-1, No 956201), Title: “DComEX: Data Driven Computational Mechanics at EXascale”, UCY budget: April 2021-March 2024. €250,000.

Cyprus Cancer Research Institute, “Enhancing adoptive T-cell therapy via T cell co-stimulation”, November 2021-October 2024. €200,000.

More information can be found at

https://www.ucy.ac.cy/cancer-biophysics/funding/